OUR EXCEPTIONAL MANUFACTURING AND R&D NETWORK

We are committed to supporting our customers with the best quality products and the highest levels of customer service. Powering this commitment is our extraordinary global manufacturing and R&D network.



OUR COMPANY AT-A-GLANCE



State-of-the Art **Manufacturing Plants**

Mid-to-Late Stage R&D programs in development

> ~\$1.5B 2016 Branded R&D Investment

> > 2016 Branded Revenue

Growth Target

THERAPEUTIC AREAS

~\$**15**B 2016 Global Branded Revenue

16,000+ **Committed Employees**

> NYSE:AGN www.Allergan.com

I am proud to introduce you to Allergan plc (NYSE:AGN), a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Our world-class team develops, manufactures and commercializes innovative branded pharmaceuticals and biologic products for patients around the world.

Allergan is one of the world's fastest growing pharmaceutical companies with a deeply established commercial presence in approximately 100 countries. Fueled by our Open Science R&D model and one of the broadest development pipelines in the industry, we are committed to innovation and addressing unmet medical needs. Together, we are carving new paths and taking bold, decisive actions that deliver results and better outcomes for patients and providers. Together, we are Allergan.



Brent Saunders CEO & President

Corporate Headquarters Clonshaugh Business & Technology Park Clonshaugh, Dublin D17 E400 Ireland

U.S. Administrative Headquarters Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054 USA









POWERING BOLD IDEAS THROUGH R&D

Allergan has built one of the broadest development pipelines in the industry through its Open Science R&D model. A high percentage of our pipeline is sourced by partnering externally with biotech companies, specialty pharmaceuticals, academia and other companies while significant dollars are continually invested in R&D. All programs enter into our best-in-class product development and commercialization platform to build a sustainable R&D portfolio. Today, Allergan has more than 65 mid-to-late stage programs in development.



GI

4

Relamorelin Diabetic

Gast oparesis

Linzess Low Dose CIC

Colonic Release CIC

Linzess

ALLERGAN'S WORLD RENOWNED BRANDS

Allergan is committed to partnering with healthcare providers to deliver innovative treatments that address medical needs across a broad spectrum of therapeutic categories.



OUR BOLD CULTURE

MEANS DOING

WHATISRIGHT

Our Company's success is powered by an unwavering commitment to act bold and make our business better, faster and stronger.

OUR CUSTOMER FOCUS

Most companies talk about the importance of customers. At Allergan, we do more than talk. We listen to our customers about their business, their needs and their challenges. We ask questions and are open to ideas. And then we take action to meet our customers' needs. We drive change to create impact. We achieve the unexpected. We get results. This is The Allergan Difference.

THE ALLERGAN DIFFERENCI WHAT IT MEANS TO

- BUILD BRIDGES
- POWER IDEAS
- DRIVE RESULTS
- ACT FAST